Churg-Strauss syndrome - Recent developments in diagnosis and treatment;Churg-Strauss-syndrom - Aktueller stand der diagnostik und therapie

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 41, 2006, Pages 2270-2274

  Hellmich, B ^a,b   Metzler, C ^a,b   Gross, W L ^a,b  

^a Rheumaklinik Bad Bramstedt   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

ANCA; Churg Strauss syndrome; Eosinophil granulocytes; Vasculitis

Indexed keywords

CYTOKINE; INTERLEUKIN 5; MYELOPEROXIDASE;

ASTHMA; CHURG STRAUSS SYNDROME; DISEASE ASSOCIATION; GERMANY; HISTOLOGY; HUMAN; INCIDENCE; MEDICAL RESEARCH; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; BRONCHOALVEOLAR LAVAGE FLUID; CHURG-STRAUSS SYNDROME; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EOSINOPHILS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERFERON-ALPHA; METHOTREXATE; PREDNISOLONE; PROGNOSIS; RADIOGRAPHY, THORACIC; RECEPTORS, TUMOR NECROSIS FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33750690162     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951362     Document Type: Review

References (30)

1. Arbach O, Gross W, Gause A. Treatment of refractory Churg-Strauss- Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206: 496-501
2. Churg A. Recent Advances in the Diagnosis of Churg-Strauss Syndrome. Mod Pathol 2001; 14: 1284-1293
3. Churg A, Brallas M, Cronin S, Churg J. Formes frustes of Churg-Strauss Syndrome. Chest 1995; 108: 320-323
4. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27: 272-301
5. Chusid M, Dale D, West B, Wolf S. The hypereosinophilic syndrome. Analysis of fourteen cases and review of the literature. Medicine 1975; 54: 1-27
6. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004; 63: 1649-1654
7. Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, Godeau B, Ruel M, Vidal E, Piontud M, Ducroix JP, Lassoued S, Christoforov B, Babinet P. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-1297
8. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78: 26-37
9. Guillevin L, Cohen P, Mahr A, Arene J, Mouthon L, Peuchal X, Pertuiset E, Gilson B, Hamidou, Lanoux P, Ruivard M, Vanhille P, Cordier J. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cylophospahmide pulses in sixty-five patients. Arthritis Rheum 2003; 49: 93-100
10. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarousse B, Lortholary O, Thibult N, Casassus P. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. Medicine 1996; 75: 17-28
11. Harrold LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM, Chan KA, Frazier EA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32: 1076-1080
12. Hellmich B, Csernok E, Gross W. Proinflammatory cytokines and autoimmunity in Churg Strauss Syndrome. Ann NY Acad Sci 2005; 1051: 121-131
13. Hellmich B, Ehlers S, Csernok E, Gross WL. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003; 21: S69-77
14. Hellmich B, Gross W. Difficult to diagnose manifestations of vasculitis: does an interdisciplinary approach help? Bailleres Best Pract Res Clin Rheumatol 2005; 19: 243-261
15. Hellmich B, Gross WL. Churg-Strauss Syndrom nach Behandlung mit Leukotrienrezeptorantagonisten: Demaskierung durch Steroidreduktion oder Nebenwirkung? Dtsch Med Wochenschr 2003; 128: 1469
16. Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5: 25-35
17. Hellmich B, Lamprecht P, Aries P, Gross W. Frühdiagnose von Vaskulitiden. Z Rheumatol 2005; 64: 538-546
18. Hellmich B, Voswinkel J, Aries P, Gross W. Primäre Systemische Vaskulitiden: Wege zur Diagnose. Dtsch Med Wochenschr 2004; 129: 1322-1327
19. Jennette J, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinico RA, Rees AJ, van Es L, Waldherr R, Wiik A. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192
20. Keogh KA, Specks U. Churg-Strauss syndrome, clinical presentation, anti-neutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115: 284-290
21. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006; 65: 557-559
22. Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63: 65-81
23. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-1100
24. Metzler C, Csernok E, Gross W, Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome. First results of a phase two open label prospective study. Arthritis Rheum 2005; 52: S648
25. Metzler C, Gross W, Hellmich B. Interferon-alpha treatment in refractory Churg-Strauss syndrome. First results of a phase II prospective open label study. Rheumatology 2005(Suppl 144: i23
26. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K. Churg Strauss syndrome - successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22: S52-61
27. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH, Raspe HH, Gross WL. No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford) 2002; 41: 540-549
28. Sable-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, Blockmans D, Cordier JF, Delaval P, Puechal X, Lauque D, Viallard JF, Zoulim A, Guillevin L. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-638
29. Solans R, Bosch J, Perez-Bocanegra C, Selva A, Huguet P, Aliijotas J, Orriols R, Armadans L, Vilardell M. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology 2001; 40: 763-771
30. Tatsis E, Schnabel A, Gross W. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129: 370-374